Iovance Biotherapeutics, Inc. IOVA Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $163.08M+41.0% | $115.69M-36.2% | $181.32M-23.9% | $238.16M+204% | ||
| $133.9M-35.7% | $208.09M+26.1% | $164.98M-31.3% | $240.11M-43.7% | ||
| $280.09M+78.5% | $156.95M+103,838% | $151K— | —— | ||
| $218.77M+61.4% | $135.57M+363% | $29.29M— | —— | ||
| $442.69M-3.1% | $457.02M+48.5% | $307.85M-35.7% | $479.12M-5.7% | ||
| $131.11M+20.2% | $109.08M-4.3% | $114.03M+8.4% | $105.23M+4.3% | ||
| $279.32M-1.1% | $282.4M+23.2% | $229.26M— | —— | ||
| $913.17M+0.3% | $910.43M+16.7% | $780.35M+17.5% | $663.98M-14.6% | ||
| $22.16M-19.4% | $27.51M-16.9% | $33.12M+24.5% | $26.6M-2.8% | ||
| $138.36M+13.1% | $122.34M+10.9% | $110.31M+20.6% | $91.49M+2.6% | ||
| $76.23M-1.9% | $77.68M-9.1% | $85.43M+17.3% | $72.86M+9.6% | ||
| $214.59M+7.3% | $200.02M+2.2% | $195.74M+19.1% | $164.34M+5.6% | ||
| $17K+30.8% | $13K+18.2% | $11K+37.5% | $8K+14.3% | ||
| -$2.78B-16.4% | -$2.38B-18.5% | -$2.01B-28.3% | -$1.57B-33.8% | ||
| $698.58M-1.7% | $710.41M+21.5% | $584.61M+17.0% | $499.64M-19.6% | ||
| $913.17M+0.3% | $910.43M+16.7% | $780.35M+17.5% | $663.98M-14.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Iovance Biotherapeutics, Inc. cover its short-term obligations?
- Its current ratio is 3.60 — current assets exceed current liabilities.
- Where does Iovance Biotherapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.